We’re excited to announce that Dr. David Ali, who has been serving as our Acting CEO and Executive Director, has been appointed as our permanent Chief Executive Officer, effective 1st July 2024. Dr. Ali will continue his role as an Executive Director.

Dr. Ali brings over 40 years of exceptional experience in medical management, business development, sales, and marketing within the pharmaceutical, medical device, and diagnostic industries, focusing on human and animal reproduction.

The Memphasys Chairman, Robert Cooke, shares his excitement:
“We are absolutely delighted to officially welcome Dr. Ali as our Chief Executive Officer on a permanent basis. His leadership has already made a significant impact, and we are confident that he will continue to drive the commercial success of our Felix™ System and spearhead new growth initiatives.”

Dr. Ali joined Memphasys in March 2023 and has been Acting CEO since November 2023. During his tenure, he has achieved notable milestones, including securing multiple international distribution agreements and accelerating sales in Japan, all while advancing Memphasys’ cutting-edge technologies.

The entire team at Memphasys wishes to congratulate David on his new position as CEO and looks forward to achieving great success under his leadership.